TY  - GEN
AU  - Costantini,Susan
AU  - Budillon,Alfredo
AU  - Costantini,Susan
AU  - Budillon,Alfredo
TI  - New Prognostic and Predictive Markers in Cancer Progression
SN  - books978-3-03943-978-2
PY  - 2021///
CY  - Basel, Switzerland
PB  - MDPI - Multidisciplinary Digital Publishing Institute
KW  - Medicine
KW  - bicssc
KW  - MSI2
KW  - OSCC
KW  - oral cancer
KW  - musashi 2
KW  - prognosis
KW  - N-cadherin
KW  - EMT
KW  - breast cancer
KW  - new metastasis
KW  - eribulin
KW  - blood
KW  - biomarker
KW  - bladder cancer
KW  - immune checkpoint inhibitor
KW  - CD8+ T effector cells
KW  - microRNA
KW  - biomarkers
KW  - head and neck cancer
KW  - laryngeal cancer
KW  - prediction
KW  - metastasis
KW  - lifestyle habit
KW  - chemo-/radio resistance
KW  - therapeutic target
KW  - AKT
KW  - AR
KW  - castration-resistant prostate cancer (CRPC)
KW  - MAPK
KW  - mTOR
KW  - PI3K
KW  - prostate cancer
KW  - therapeutic resistance
KW  - WNT
KW  - miRNA
KW  - melanoma
KW  - melanoma resistance to MAPK/MEK inhibitors
KW  - resistance to immune checkpoint inhibitors
KW  - TNBC
KW  - BRCA1/2
KW  - HRR
KW  - PDL1
KW  - TILs
KW  - PI3KCA
KW  - PTEN
KW  - CTCs
KW  - CSC
KW  - pancreatic cancer
KW  - K-RAS oncogene
KW  - oncogene dependency
KW  - targeted therapies
KW  - genomic mutations
KW  - transcriptomics
KW  - metabolomics
KW  - selenoproteins
KW  - cancer
KW  - HUB nodes
KW  - major histocompatibility complex (MHC)
KW  - human leukocyte antigen (HLA)
KW  - antigen processing machinery (APM) molecules
KW  - carcinogenesis
KW  - tumor predisposition
KW  - cancer immunotherapy
KW  - pheochromocytoma
KW  - paraganglioma
KW  - head and neck neoplasms
KW  - head and neck tumors
KW  - genetic syndromes
KW  - mutations
KW  - hyperglycemia
KW  - cardioncology
KW  - nivolumab
KW  - cytokines
KW  - cardiotoxicity
KW  - acetyltransferase
KW  - cancer prognosis
KW  - NAA10
KW  - n/a
N1  - Open Access
N2  - Biomarkers are of critical medical importance for oncologists, allowing them to predict and detect disease and to determine the best course of action for cancer patient care. Prognostic markers are used to evaluate a patient's outcome and cancer recurrence probability after initial interventions such as surgery or drug treatments and, hence, to select follow-up and further treatment strategies. On the other hand, predictive markers are increasingly being used to evaluate the probability of benefit from clinical intervention(s), driving personalized medicine. Evolving technologies and the increasing availability of "multiomics" data are leading to the selection of numerous potential biomarkers, based on DNA, RNA, miRNA, protein, and metabolic alterations within cancer cells or tumor microenvironment, that may be combined with clinical and pathological data to greatly improve the prediction of both cancer progression and therapeutic treatment responses. However, in recent years, few biomarkers have progressed from discovery to become validated tools to be used in clinical practice. This Special Issue comprises eight review articles and five original studies on novel potential prognostic and predictive markers for different cancer types
UR  - https://mdpi.com/books/pdfview/book/3386
UR  - https://directory.doabooks.org/handle/20.500.12854/68373
ER  -